In order to test the hypothesis that GABA is an inhibitory neurotransmitter restricting the release of LHRH before puberty, we examined the effects of pulsatile infusion of the GABA A receptor blocker, bicuculline, on the timing of puberty. Eleven female monkeys at 14 -15 months of age were implanted with a stainless steel cannula into the base of the third ventricle above the median eminence. Five monkeys received bicuculline infusion every 2 h at a dose of 1 M with a gradual increase to 100 M in 10 l using a portable infusion pump. The remaining 6 monkeys received similar infusions of saline. An additional 11 colony monkeys without cannula implantation were used for controls. Results indicate that bicuculline infusion advances the timing of puberty. The age of menarche (17.8 Ϯ 0.5 months) in the bicuculline infusion animals was significantly earlier than that in the saline controls (28.2 Ϯ 2.3, P Ͻ 0.001) as well as in colony controls (30.6 Ϯ 0.9, P Ͻ 0.001). The age of first ovulation (30.5 Ϯ 3.3 months) in bicuculline-treated animals was much younger (P Ͻ 0.001) than that in both controls (44.8 Ϯ 1.8 and 44.7 Ϯ 1.2, respectively). Bicuculline also accelerated the growth curve. These results suggest that the reduction of tonic GABA inhibition of LHRH neurons advances the onset of puberty. (Endocrinology 140: [5257][5258][5259][5260][5261][5262][5263][5264][5265][5266] 1999) 
I T HAS BEEN speculated for the past two decades, that in
primates there is a "central inhibition" of LH release, and presumably LHRH release, starting shortly after the neonatal period and ending before the onset of puberty (1) (2) (3) . This concept is based upon the fact that 1) despite the absence of gonads, LH levels in children with Turner's syndrome and in neonatally castrated juvenile monkeys were as low as those in their gonadally intact counterparts (1, 2, 4, 5) , and 2) lesions in the hypothalamus resulted in precocious puberty in primates (6, 7) . Although it has been argued that induction of precocious puberty with hypothalamic lesions may be due to a stimulatory signal rather than removal of inhibition (8) , the data that the LH secretory pattern in neonatal male monkeys is similar to adult males, but differs from juvenile males (2) , clearly support the concept of central inhibition in primates. Nonetheless, the specific mechanism of this central inhibition of LH/LHRH release is unknown. If an inhibitory neurotransmitter produces tonic inhibition of the LHRH neurosecretory system, it may be implicated as a component of central inhibition.
␥-Amino butyric acid (GABA) is the major inhibitory neurotransmitter in the hypothalamus (9) . The inhibitory role of GABA in the preovulatory gonadotropin surge and puberty has been reported in rats and sheep (10 -12) . Previously, we have hypothesized that the LHRH neuronal system in primates is tonically inhibited by GABA neurons before the onset of puberty and that reduction of GABA inhibition triggers the onset of puberty. This hypothesis is based on several observations in this laboratory. First, GABA levels in the stalk-median eminence (S-ME) in prepubertal monkeys were much higher than in midpubertal monkeys (13, 14) . Second, the GABA A receptor blocker, bicuculline, but not the GABA B receptor blocker, saclofen, stimulated LHRH release in prepubertal monkeys by removing endogenous GABA inhibition (13) , whereas exogenous GABA was not effective in suppressing LHRH release until after the onset of puberty (13) , when endogenous GABAergic tone is reduced. Third, infusion of antisense oligodeoxynucleotides for glutamic acid decarboxylase (GAD67 and GAD65) messenger RNAs (mRNAs) into the S-ME of prepubertal monkeys resulted in a dramatic increase in LHRH release (15, 16) , presumably due to the reduction of synthesis and release of GABA. GAD67 and GAD65, derived from two different genes, are the catalytic enzymes for GABA synthesis from glutamate. In vivo perfusion of an antisense oligodeoxynucleotide for GAD67 mRNA into the S-ME of pubertal monkeys also resulted in an increase in LHRH release, but the magnitude of this increase was much smaller than that seen in prepubertal monkeys (16) , indicating that GABA inhibition is not completely removed at the onset of puberty, but is weakened. Fourth, the antisense GAD 67-induced LHRH increase was accompanied by a decrease in GABA release, followed by an increase in glutamate release (14) .
If GABA is an inhibitory neurotransmitter responsible for the timing of puberty, infusion of the GABA A receptor blocker, bicuculline, into the base of the third ventricle above the ME would trigger puberty by reducing endogenous GABA input to the LHRH neuronal system. In the present study, we examined this possibility. The results indicate that bicuculline infusion induces precocious puberty in female rhesus monkeys.
Materials and Methods Animals
Eleven female rhesus monkeys (Macaca mulatta) at 12-13 months of age, born and raised at the Wisconsin Regional Primate Research Center (Madison, WI), were assigned to this study. All animals were weaned at 10 months of age and housed in a room with controlled lighting (12-h light, 12-h dark, lights on 0600) and temperature (22 C). Monkeys were fed a standard diet of Purina Monkey Chow daily, supplemented with fresh fruit several times per week. Water was available ad libitum. Before surgery all monkeys were gradually adapted to a monkey jacket over a period of 4 weeks. The protocol for this study was reviewed and approved by the Animal Care and Use Committee, University of Wisconsin, and all experiments were performed under the guidelines established by the NIH and USDA.
Surgery
To infuse bicuculline into the base of the third ventricle, all monkeys received stereotaxic implantation of a stainless steel cannula with a double lumen (20-gauge outer cannula and 23-gauge inner cannula) into the base of the third ventricle ( Fig. 1) under isoflurane anesthesia. The third ventricle and bone structures were visualized with x-ray ventriculograms before cannula implantation, as described previously (17) . The cannula was secured with dental acrylic and screws to the skull, and the inner cannula was connected to either a SILASTIC brand silicon tube (Dow Corning, Midland, MI) or tygon tube, which was exteriorized between the shoulder blades. The tube was then connected to a small portable infusion pump (Disetronic Medical Systems, Inc., Minneapolis, MN).
Bicuculline infusion
After cannula implantation, all monkeys received saline infusion to maintain the patency of the cannula. After 7-10 days, 5 of 11 monkeys were infused with (-)-bicuculline methiodide (Sigma, St. Louis, MO) every 2 h at a dose of 1 m in 10 l for 4 weeks. Bicuculline concentration was increased to 10 m for 4 weeks at the same rate and volume, and further increased to 100 m at the same rate and volume for the rest of the experiment. Bicuculline was dissolved in saline solution and filtered before use. The infusion pump was housed inside a small back pocket in a monkey jacket. The remaining 6 monkeys received similar infusions of saline. During the entire experiment, animals were completely free from any physical restraint. The infusion pump was replenished with bicuculline or saline solution every 2 weeks under light ketamine anesthesia (5 mg/kg, ketamine hydrochloride, Fort Dodge Animal Health, Fort Dodge, IA). In some animals, the tube connecting the cranial cannula and pump was occasionally disconnected, despite the close and frequent inspections of animals. When this occurred the tube was reconnected under ketamine (10 mg/kg) with xylazine (0.5 mg/kg, Phoenix Pharmaceuticals, Inc. Inc., St. Joseph, MO) anesthesia as soon as possible. Antibiotics and sulfa drugs, such as Naxcel (0.5 mg/kg, Pharmacia & Upjohn, Inc. Co., Kalamazoo, MI), Cefazolin (20 mg/kg, Marsam Pharmaceutical Inc., Cherry Hill, NJ) or Baytril (5 mg/kg, Bayer Corp., Shawnee Mission, KS) were used after surgeries and if any infections occurred during the experiment. Disruption of infusion due to occlusions or tubing disconnection occurred in both bicuculline-treated animals and saline controls with a similar frequency, which was not related to the timing of menarche or first ovulation. We terminated intracranial infusion in each animal after the confirmation of the second ovulation and removed the cannula and infusion pump. We followed ovulatory cycles in the bicuculline-treated animals until the normal age of ovulation (45-48 months). To compare the ages of menarche, and first and second ovulations, an additional 11 colony monkeys without cannula implantation were used for controls.
Observation of developmental processes
Hormonal and physical changes during pubertal development were obtained as follows. Weekly blood samples were taken via femoral puncture at 0830 and 2030 h on the same day, starting at least 3 weeks before surgery until the confirmation of two ovulations in all animals. Body weight was also measured weekly. To keep animals as undisturbed as possible, more frequent blood sampling was not conducted. Sex-skin color index, menarche, and subsequent menstruations were observed and recorded daily as described previously (6) . The occurrence of ovulation was assessed by the break-down of sex-skin color followed by progesterone levels above 1 ng/ml (6) .
Hormone assays
LH, FSH, estradiol, progesterone, and GH in serum samples were measured by RIA. LH and FSH levels were measured in all samples. However, due to the limited volume, estradiol was measured in morning samples, whereas progesterone and GH were measured in evening FIG. 1. Schematic illustration of the cannula position in the base of the third ventricle above the median eminence. The head of the monkeys was placed in the stereotaxic apparatus, and the ventricular system was visualized with a radio contrast medium. FM, Foramen of Monro; L, lateral ventricle; oc, optic chiasm; PT, pituitary, III, third ventricle.
samples. To confirm ovulation, progesterone levels in the morning samples were also measured when evening levels reached Ͼ1 ng/ml. Assays for LH, estradiol, and progesterone, were described previously (5, 6, 18) . FSH levels were estimated by a heterologous immunoassay with antiovine FSH (H-31, supplied by Dr. Gary D. Hodgen), human FSH trace (hFSH-I-3, National Hormone Pituitary Program, 4822B), and reference preparation (cynFSH-RP-1, National Hormone Pituitary Program). The sensitivity was 3 ng/ml, and the intra and interassay coefficients of variation (cv) were 3.8% and 12.6%, respectively. The results from the FSH assay have been reported (19) . For GH assay we employed antihuman GH (National Hormone Pituitary Program, C11981B) for the 1st antibody, monkey GH (National Hormone Pituitary Program, 5892C) for trace, and human GH-RP1 (National Hormone Pituitary Program, 4793B) for the standard. Sensitivity was 0.1 ng/ml and the intra and interassay cv were 3.9% and 6.1%, respectively.
Statistical analysis
The average age in months at menarche, first ovulation and second ovulations were compared among the three groups, using ANOVA followed by a post hoc analysis with Student's-Newman-Keuls' multiple range test. The body weights at menarche, and first and second ovulations among groups were similarly compared. Effects of the bicuculline treatment on the LH, FSH, estrogen and GH levels, and developmental changes in LH, FSH, estrogen, and GH were examined with two-way ANOVA, followed by a post hoc analysis using the StudentNewman-Keuls' multiple range test. Significance was set at P Ͻ 0.05.
Results

Timing of puberty
First of all, bicuculline infusion did not cause any apparent toxic effects. All 5 bicuculline-treated animals started to exhibit a slight increase in perineal sex-skin swelling by 3-4 weeks after the initiation of infusion. Three of the 5 monkeys reached menarche after 1.4 -1.9 months, whereas the remaining 2 monkeys reached menarche 4.3-4.7 months after the initiation of bicuculline infusion. In contrast, none of the saline controls exhibited these changes for several months. Average (Ϯsem) age of menarche in the 5 bicuculline infusion animals (17.8 Ϯ 0.5 months) was significantly younger than that of the 6 saline controls (28.2 Ϯ 2.3, P Ͻ 0.001) or in colony controls (30.5 Ϯ 0.9, n ϭ 11, P Ͻ 0.001, Table 1 and Fig. 2A) .
The bicuculline-and saline-treated animals exhibited repeated menstrual episodes before first ovulation. First ovulation in 4 of the 5 bicuculline-treated animals occurred at less than 30 months of age (as early as 24 months of age), whereas the remaining 1 monkey ovulated at 42.9 months of age. It is noteworthy to point out that first ovulation in the four bicuculline-treated animals occurred even before the average age of menarche in colony controls. The monkey that ovulated at 42.9 months was the youngest (14.3 months of age) and smallest (less than 2 kg) monkey among all the subjects when the experiment was initiated and her cannula was replaced at 34 months of age due to the loss of its patency. The age of first ovulation (30.5 Ϯ 3.3 months) in bicucullinetreated animals, was much younger (P Ͻ 0.001, Table 1 , Fig.  2B ) than that of saline controls (44.8 Ϯ 1.8) and colony controls (44.7 Ϯ 1.2). Similarly, the age (33.7 Ϯ 2.9 months) of second ovulation in bicuculline-treated animals was younger (P Ͻ 0.001, Table 1 , Fig. 2C ) than that of saline controls (46.1 Ϯ 2.0) or colony controls (45.7 Ϯ 1.2).
The interval between the menarche and first ovulation in bicuculline-and saline-treated group was not significantly different (13.3 Ϯ 2.9 vs. 16.7 Ϯ 2.9 months). The interval between first and second ovulations (2.6 Ϯ 0.7 months, Table  1 , Fig. 3 ) in the bicuculline-treated animals tended to be longer than that in colony controls (1.2 Ϯ 0.1 months) as well as saline controls (1.3 Ϯ 0.3 months, Table 1 , Fig. 4 ), although the means were not significant (P Ͻ 0.1 for both).
Interestingly, the four bicuculline-treated animals that ovulated at the younger age did stop exhibiting ovulatory cycles when bicuculline infusion was terminated, and did not resume their ovulatory cycles until they reached the normal age that ovulation occurs.
Hormonal changes
In the bicuculline-treated animals, the nocturnal increase in LH release started to occur shortly after the initiation of bicuculline infusion as shown in Fig. 3A . In contrast, in saline controls, the nocturnal LH increase did not occur until around or after 20 months of age (Fig. 4A ). Group data (Fig.  5 ) indicated that there were developmental changes in LH release in both bicuculline and saline groups (P Ͻ 0.001 for both). The treatment effect of bicuculline was significant for both the morning and evening values (P Ͻ 0.05 and P Ͻ 0.001, respectively). Further, evening LH values were significantly higher than morning LH values in both bicuculline and saline groups (P Ͻ 0.005 for mornings and P Ͻ 0.001 for evening). However, the significant interaction between the treatment effect and age or the morning-evening effect and age was not observed.
An increased release of FSH was also evident right after the initiation of bicuculline infusion (before menarche) (Fig.  3B) , whereas the pubertal increase in FSH did not occur until 2-3 months before menarche in saline controls (Fig. 4B ). There were clear developmental effects on FSH in both bicuculline and saline groups (P Ͻ 0.01 for both, Fig. 6 ) and there was a significant effect of bicuculline on FSH levels (P Ͻ 0.01, Fig. 6 ). Post hoc analysis indicated that FSH levels in the bicuculline-treated group were significantly higher than those in the saline group between 16 -27 months of age (Fig. 6) . Similarly, estrogen started to increase right after the initiation of bicuculline infusion (Fig. 3C) , whereas it did not start to increase until a few months before menarche in the saline group (Fig. 4C) . Analysis of group data indicated that there were clear developmental changes in estrogen in both groups (P Ͻ 0.01 for both), and there was a bicuculline treatment effect on estrogen levels (P Ͻ 0.05, Fig. 7) . Post hoc analysis showed that estrogen levels in the bicuculline group were significantly higher than those in the saline controls at 16 -19 months and 24 -29 months of age (Fig. 7) . Repeated elevations of progesterone above 1 ng/ml in bicucullinetreated monkeys (Fig. 3C ) before 30 months of age indicated that they ovulated at a younger age than saline controls (Fig.  4C ). Progesterone levels (1.8 Ϯ 0.5 ng/ml) at first ovulation in the bicuculline-treated monkeys tended to be lower than those (2.7 Ϯ 1.4 ng/ml) in saline controls (not significant), but were significantly lower than in colony controls (3.9 Ϯ 0.6 ng/ml, P Ͻ 0.02). Progesterone levels (1.9 Ϯ 0.3 ng/ml) at second ovulation in the bicuculline-treated monkeys were significantly lower than those in saline controls (5.9 Ϯ 1.0 ng/ml, P Ͻ 0.01) as well as in colony controls (3.5 Ϯ 0.5 ng/ml, P Ͻ 0.01).
GH levels were relatively high right after cannula implantation in both bicuculline and saline controls (Fig. 8) . However, while GH levels in saline controls became low by 20 months of age, and remained low through two ovulations (Fig. 8B) , high GH levels in bicuculline animals continued through two ovulations (Fig. 8A) . Group data indicated that there was a significant effect of the bicuculline treatment on GH (P Ͻ 0.01, Fig. 8C ). Post hoc analysis indicated that mean GH levels in the bicuculline group at 20 -31 months of age were higher than those in the saline group (Fig. 8C) .
Changes in body weight
Bicuculline treatment also accelerated the body weight growth curve, whereas saline treatment retarded it ( Table 1) . The body weights of bicuculline-treated monkeys were consistently higher than that of colony controls or saline controls, until 32-34 months of age ( Fig. 9 , P Ͻ 0.001). In contrast, the body weights of saline controls were consistently smaller than colony controls until age of first ovulation ( Fig. 9 , P Ͻ 0.001). Nonetheless, the body weights at menarche, first ovulation, and second ovulation in bicuculline-treated monkeys were only lower than those of colony controls, but did not differ from those of saline controls (Table 1) .
Discussion
In the present study we found that pulsatile infusion of the GABA A receptor blocker, bicuculline, resulted in precocious puberty. Ages at menarche and first ovulation in the bicuculline-treated animals were significantly (P Ͻ 0.001) younger than saline controls or colony controls. The average age of menarche at less than 18 months is astonishingly younger because there is no sign of puberty in the normal female at this age. Ordinarily, animals at this age would be prepubertal (1) . Similarly, the average ages of first and second ovulations at 30.5 and 33.7 months, respectively, are also very young. In fact, the average age of first ovulation in the bicuculline-treated animals is just about the age of menarche in colony controls. Further, throughout other experiments to induce precocious puberty such as with lesions in the posterior hypothalamus (6) and transplantation of the adrenal medulla into the hypothalamus (20), we have not seen menarche or ovulation at such a young age. Moreover, hormonal changes associated with puberty, such as increases in circulating LH, FSH, and estrogen, and the nocturnal increase in LH release in the bicuculline-treated animals, occurred at much younger ages than in saline controls.
The observation that increases in circulating LH, FSH, and estrogen occurred 2-3 weeks after the initiation of bicuculline infusion suggests that the blockade of GABA A receptors indeed stimulated LHRH release from the hypothalamus. Previously, we have shown that direct infusion of bicuculline into the S-ME stimulated LHRH release (13) . Thus, the reduction in GABA triggers the cascade of LHRH release, followed by gonadotropin and estrogen secretion, and subsequent menarche occurring at 6 -20 weeks. In contrast to this prompt effect on age of menarche, it took an additional 8 -12 months for first ovulation. Because the time between menarche and first ovulation in saline controls and colony females is 12-16 months, bicuculline infusion slightly shortened this interval. Nonetheless, the question arises as to why the bicuculline-induced LHRH increase is not sufficient to result in first ovulation right after menarche? To answer this question, we need to discuss two important points.
First, the hypothalamic mechanism involved in the timing of first ovulation appears to differ from that of menarche, even though both require an increase in pulsatile LHRH release. There are several examples of experimental manipulations in the female rhesus monkey in which the timing of first ovulation was altered without changing the timing of menarche. Transplantation of the adrenal medulla, which contains catecholamines and neuropeptide-Y (NPY), only advanced the age of the first ovulation, but not menarche (20) . The long-term administration of GH into juvenile female monkeys accelerated the timing of first ovulation, but not menarche (21) . Similarly, treatments with IGF-1 advanced the timing of first ovulation, whereas it did not alter the timing of menarche (22) . In contrast, administration of a somatostatin analog delayed the timing of first ovulation, but not menarche (23) . Further, because in the IGF-1 treatment experiment, the LH response to NMDA challenge in animals at the age of first ovulation was larger than that in animals at the menarcheal age, independent from pituitary sensitivity, Wilson (22) concluded that the sensitivity of the LHRH neurosecretory system to NMDA was altered before first ovulation.
Second, a larger amount of LHRH output appears to be required for the positive-feedback effects of estrogen in the pubertal rhesus monkey. Evidence to support this speculation is as follows: 1) Escape from estrogen suppression or a decrease in hypersensitivity to estrogen in ovariectomized female monkeys, occurred at the age of first ovulation, but not at the age of menarche (24, 25) ; 2) Although the positivefeedback effects of estrogen on the LH surge in ovariectomized monkeys starts to occur at the menarcheal age (26, 27) , the amplitude of the LH response to estrogen continuously increases until the age of first ovulation (27) ; and 3) Direct measurement of LHRH release from the S-ME indicates that an increase in pulsatile LHRH release (pulse frequency, pulse amplitude, and basal release) occurs at the onset of puberty, but a total output of LHRH release (pulse amplitude and basal release) further increases between early and midpubertal stages in female rhesus monkeys (28, 29) . It has been reported that hourly infusion of LHRH (6 g) into juvenile female monkeys by a pump, through the general circulation, resulted in menarche by 7-8 weeks followed by first ovulation by 9 -10 weeks after the initiation of infusion (30) . Priming the gonadotrophs by the pulsatile administration of LHRH with the same protocol in ovariectomized adult monkeys, whose LHRH pulsegenerating mechanism is eliminated by lesions, is sufficient to result in the estrogen-induced gonadotropin surge (31) . Therefore, the 6 g/h infusion of LHRH is sufficient to induce menarche as well as the preovulatory gonadotropin surge in ovarian intact juvenile female monkeys. In contrast, the increase in LHRH release induced by bicuculline in this study is probably not as large as LHRH infusion by a pump (30) , and thus insufficient to induce positive-feedback effects of estrogen, even though it is sufficient to result in menarche.
The results of the present study suggest that a reduction of GABA inhibition can trigger the onset of the pubertal increase in LHRH release. A series of studies from this laboratory further suggest that the reduction in GABA release is followed by an increase in glutamate release in the S-ME (14, 16) . In fact, a pubertal increase in glutamate appears to occur promptly after GABA reduction. For instance, when an antisense oligodeoxynucleotide for GAD 67 mRNA was infused into the S-ME, a glutamate increase occurred shortly after a GABA reduction (14) , and the antisense-GAD 67- induced LHRH release was indeed blocked by the NMDA blocker MK801 (16) . Because glutamate, an excitatory neurotransmitter, plays an important role in puberty (32) (33) (34) (35) , an increase in glutamate release in the S-ME undoubtedly contributes to further increase LHRH release during the progress of puberty. How quickly GABA reduction is followed by glutamate increase at the spontaneous onset of puberty has not been studied.
Systemic infusion of N-methyl-d-aspartate (NMDA) in juvenile male monkeys at 15-16 months of age resulted in testicular growth with spermatogenesis comparable to that of adult males by 16 -30 weeks (36) . Because the effects of NMDA were blocked by simultaneous infusion of an LHRH antagonist, it is assumed that NMDA stimulated LHRH release from the hypothalamus. Because investigation into the effects of NMDA infusion on precocious puberty in female monkeys has not been conducted, direct comparisons cannot be made. Nonetheless, the timing required for the initial response of the testis to the NMDA-induced LHRH/gonadotropin secretion (36) and that of the ovary to the bicucullineinduced LHRH/gonadotropin secretion in this study appears to be similar, although the timing required for the final maturation of the testis and the ovary with these treatments appears to be dissimilar.
There are consistent data to support the concept that the reduction in GABA is followed not only by an increase in glutamatergic input, but also by other stimulatory and inhibitory inputs to the LHRH neuronal system. We have reported that NPY and norepinephrine neuronal systems were both important for the advanced stage of puberty, rather than at the onset of puberty (37, 38) . Further, evidence indicates that inhibitory opiatergic input to the LHRH neuronal system became active after the onset of puberty (39 -42) . Therefore, it is hypothesized that the period between menarche and first ovulation is required for maturation of the stimulatory and inhibitory regulatory mechanisms for a large amount of LHRH release.
The fact that when the bicuculline infusion was terminated, precocious puberty induced by bicuculline is halted, indicates that 1) the immature hypothalamic mechanism for cyclic ovulation is driven by bicuculline infusion, and 2) GABA inhibition continues after the onset of puberty as well as after the incidence of first ovulation. A previous observation that infusion of an antisense oligodeoxynucleotide into the S-ME of pubertal monkeys stimulated LHRH release, although the LHRH response in the pubertal monkeys was much smaller than that in prepubertal monkeys (16) , supports this notion.
The results that the interval between first and second ovulations in bicuculline-treated animals tended to be longer than controls, and that progesterone levels after first and second ovuations in bicuculline-treated animals were less than those in controls, appear to indicate that precoscious puberty with the GABA antagonist may not represent the normal pubertal process. Any abnormalities may be due to the parameters of bicuculline infusion, such as frequency and doses. Whether precoscious puberty by other approaches exhibits similar characteristics in the progesterone profile or this is specific to GABA disinhibition is unknown.
Saline infusion retarded body weight suggesting that the cannula placement in the third ventricle and infusion procedure were slightly stressful to the animals. However, bicuculline infusion resulted in accelerated growth, when compared with normal controls. It has been shown that the body weight increase in monkeys at 12 to 50 months is parallel to bone growth (43) . Because we did not measure GH levels in untreated controls, it is difficult to speculate whether elevated levels of GH in both bicuculline-treated animals and saline controls before 19 months of age are due to maturational changes or to procedural. Nonetheless, GH levels in bicuculline-treated monkeys at 19 -31 months were higher than in saline controls. These data are interpreted to mean that 1) a premature increase in estrogen with bicuculline treatment may directly stimulate epiphysial growth and indirectly stimulate it through the release of GHRH, GH and IGF-1, and/or 2) bicuculline infusion into the S-ME of juvenile monkeys disinhibits the GH-releasing hormone (GHRH) neurons/neuroterminals, thus stimulating GH release. It is of interest to further study if GABA neurons mediate the interaction between the LHRH neuronal system and/or the GHRH/somatostatin neuronal system in the hypothalamus at the onset of puberty, as well as during the progress of puberty.
In summary, in the present study pulsatile infusion of a GABA A receptor antagonist, bicuculline, advanced the tim- Note that the body weight of bicuculline-treated monkeys was consistently higher than that of colony controls or saline controls (P Ͻ 0.001). In contrast, the body weight of saline controls was consistently smaller than the colony controls until age of first ovulation (P Ͻ 0.001).
ing of menarche and first ovulation. The results suggest that the reduction of inhibitory input to LHRH neurons from GABA neurons is the key factor for initiation of the onset of puberty. However, it takes several months for ovulation to occur after menarche, indicating that subsequent establishment of facilitatory and inhibitory inputs to LHRH neurons is required during the pubertal process. The mechanism of the reduction of inhibitory GABA input to LHRH release remains to be investigated.
